INTELLIPHARMACEUTICS INTERNA (IPCI.CA) Stock Fundamental Analysis

TSX:IPCI • CA4581733090

0.08 CAD
-0.01 (-11.11%)
Last: Mar 5, 2024, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, IPCI scores 1 out of 10 in our fundamental rating. IPCI was compared to 34 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IPCI have multiple concerns. IPCI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • IPCI had negative earnings in the past year.
  • IPCI had a positive operating cash flow in the past year.
IPCI.CA Yearly Net Income VS EBIT VS OCF VS FCFIPCI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -202.69%, IPCI is doing worse than 85.37% of the companies in the same industry.
Industry RankSector Rank
ROA -202.69%
ROE N/A
ROIC N/A
ROA(3y)-182.47%
ROA(5y)-175.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IPCI.CA Yearly ROA, ROE, ROICIPCI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IPCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPCI.CA Yearly Profit, Operating, Gross MarginsIPCI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • IPCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IPCI has about the same amount of shares outstanding.
  • IPCI has a worse debt/assets ratio than last year.
IPCI.CA Yearly Shares OutstandingIPCI.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
IPCI.CA Yearly Total Debt VS Total AssetsIPCI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

2.2 Solvency

  • IPCI has an Altman-Z score of -111.24. This is a bad value and indicates that IPCI is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -111.24, IPCI is doing worse than 92.68% of the companies in the same industry.
  • The Debt to FCF ratio of IPCI is 18.06, which is on the high side as it means it would take IPCI, 18.06 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 18.06, IPCI is in the better half of the industry, outperforming 70.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 18.06
Altman-Z -111.24
ROIC/WACCN/A
WACC5.78%
IPCI.CA Yearly LT Debt VS Equity VS FCFIPCI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -5M -10M

2.3 Liquidity

  • IPCI has a Current Ratio of 0.06. This is a bad value and indicates that IPCI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.06, IPCI is doing worse than 95.12% of the companies in the same industry.
  • IPCI has a Quick Ratio of 0.06. This is a bad value and indicates that IPCI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • IPCI's Quick ratio of 0.06 is on the low side compared to the rest of the industry. IPCI is outperformed by 95.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
IPCI.CA Yearly Current Assets VS Current LiabilitesIPCI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.14% over the past year.
  • IPCI shows a strong growth in Revenue. In the last year, the Revenue has grown by 783.04%.
  • Measured over the past years, IPCI shows a very negative growth in Revenue. The Revenue has been decreasing by -58.74% on average per year.
EPS 1Y (TTM)20.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-537.88%
Revenue 1Y (TTM)783.04%
Revenue growth 3Y-73.37%
Revenue growth 5Y-58.74%
Sales Q2Q%260.36%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IPCI.CA Yearly Revenue VS EstimatesIPCI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2022 1M 2M 3M 4M 5M
IPCI.CA Yearly EPS VS EstimatesIPCI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IPCI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPCI.CA Price Earnings VS Forward Price EarningsIPCI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IPCI indicates a somewhat cheap valuation: IPCI is cheaper than 73.17% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 17.19
EV/EBITDA N/A
IPCI.CA Per share dataIPCI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IPCI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

INTELLIPHARMACEUTICS INTERNA

TSX:IPCI (3/5/2024, 7:00:00 PM)

0.08

-0.01 (-11.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.63%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.80M
Revenue(TTM)904.94K
Net Income(TTM)-3.17M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.29
P/FCF 17.19
P/OCF 17.19
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY5.82%
OCF(TTM)0
OCFY5.82%
SpS0.03
BVpS-0.5
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -202.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 13.31%
ROA(3y)-182.47%
ROA(5y)-175.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 18.06
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -111.24
F-Score7
WACC5.78%
ROIC/WACCN/A
Cap/Depr(3y)0%
Cap/Depr(5y)3.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-537.88%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)783.04%
Revenue growth 3Y-73.37%
Revenue growth 5Y-58.74%
Sales Q2Q%260.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y104.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y104.39%
OCF growth 3YN/A
OCF growth 5YN/A

INTELLIPHARMACEUTICS INTERNA / IPCI.CA FAQ

What is the fundamental rating for IPCI stock?

ChartMill assigns a fundamental rating of 1 / 10 to IPCI.CA.


What is the valuation status of INTELLIPHARMACEUTICS INTERNA (IPCI.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to INTELLIPHARMACEUTICS INTERNA (IPCI.CA). This can be considered as Overvalued.


What is the profitability of IPCI stock?

INTELLIPHARMACEUTICS INTERNA (IPCI.CA) has a profitability rating of 0 / 10.